Search

Your search keyword '"Choy, Hak"' showing total 683 results
Start Over Author "Choy, Hak"
683 results on '"Choy, Hak"'

2. Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.

Author

Bezjak, Andrea, Paulus, Rebecca, Gaspar, Laurie E, Timmerman, Robert D, Straube, William L, Ryan, William F, Garces, Yolanda I, Pu, Anthony T, Singh, Anurag K, Videtic, Gregory M, McGarry, Ronald C, Iyengar, Puneeth, Pantarotto, Jason R, Urbanic, James J, Sun, Alexander Y, Daly, Megan E, Grills, Inga S, Sperduto, Paul, Normolle, Daniel P, Bradley, Jeffrey D, and Choy, Hak

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Lung, Clinical Research, Lung Cancer, Clinical Trials and Supportive Activities, Cancer, Evaluation of treatments and therapeutic interventions, 6.5 Radiotherapy and other non-invasive therapies, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Dose Fractionation, Radiation, Dose-Response Relationship, Radiation, Female, Humans, Lung Neoplasms, Male, Middle Aged, Radiosurgery, Treatment Outcome, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposePatients with centrally located early-stage non-small-cell lung cancer (NSCLC) are at a higher risk of toxicity from high-dose ablative radiotherapy. NRG Oncology/RTOG 0813 was a phase I/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of stereotactic body radiotherapy (SBRT) for centrally located NSCLC.Materials and methodsMedically inoperable patients with biopsy-proven, positron emission tomography-staged T1 to 2 (≤ 5 cm) N0M0 centrally located NSCLC were accrued into a dose-escalating, five-fraction SBRT schedule that ranged from 10 to 12 Gy/fraction (fx) delivered over 1.5 to 2 weeks. Dose-limiting toxicity (DLT) was defined as any treatment-related grade 3 or worse predefined toxicity that occurred within the first year. MTD was defined as the SBRT dose at which the probability of DLT was closest to 20% without exceeding it.ResultsOne hundred twenty patients were accrued between February 2009 and September 2013. Patients were elderly, there were slightly more females, and the majority had a performance status of 0 to 1. Most cancers were T1 (65%) and squamous cell (45%). Organs closest to planning target volume/most at risk were the main bronchus and large vessels. Median follow-up was 37.9 months. Five patients experienced DLTs; MTD was 12.0 Gy/fx, which had a probability of a DLT of 7.2% (95% CI, 2.8% to 14.5%). Two-year rates for the 71 evaluable patients in the 11.5 and 12.0 Gy/fx cohorts were local control, 89.4% (90% CI, 81.6% to 97.4%) and 87.9% (90% CI, 78.8% to 97.0%); overall survival, 67.9% (95% CI, 50.4% to 80.3%) and 72.7% (95% CI, 54.1% to 84.8%); and progression-free survival, 52.2% (95% CI, 35.3% to 66.6%) and 54.5% (95% CI, 36.3% to 69.6%), respectively.ConclusionThe MTD for this study was 12.0 Gy/fx; it was associated with 7.2% DLTs and high rates of tumor control. Outcomes in this medically inoperable group of mostly elderly patients with comorbidities were comparable with that of patients with peripheral early-stage tumors.

Published
2019

3. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer

Author

Videtic, Gregory M, Paulus, Rebecca, Singh, Anurag K, Chang, Joe Y, Parker, William, Olivier, Kenneth R, Timmerman, Robert D, Komaki, Ritsuko R, Urbanic, James J, Stephans, Kevin L, Yom, Sue S, Robinson, Clifford G, Belani, Chandra P, Iyengar, Puneeth, Ajlouni, Munther I, Gopaul, Darindra D, Gomez Suescun, Jorge B, McGarry, Ronald C, Choy, Hak, and Bradley, Jeffrey D

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Lung, Prevention, Cancer, Lung Cancer, Clinical Research, Clinical Trials and Supportive Activities, 6.5 Radiotherapy and other non-invasive therapies, Evaluation of treatments and therapeutic interventions, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Confidence Intervals, Dose Fractionation, Radiation, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Progression-Free Survival, Radiation Injuries, Radiosurgery, Time Factors, Treatment Failure, Other Physical Sciences, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis, Theoretical and computational chemistry, Medical and biological physics
Abstract

PurposeTo present long-term results of RTOG 0915/NCCTG N0927, a randomized lung stereotactic body radiation therapy trial of 34 Gy in 1 fraction versus 48 Gy in 4 fractions.Methods and materialsThis was a phase 2 multicenter study of patients with medically inoperable non-small cell lung cancer with biopsy-proven peripheral T1 or T2 N0M0 tumors, with 1-year toxicity rates as the primary endpoint and selected failure and survival outcomes as secondary endpoints. The study opened in September 2009 and closed in March 2011. Final data were analyzed through May 17, 2018.ResultsEighty-four of 94 patients accrued were eligible for analysis: 39 in arm 1 and 45 in arm 2. Median follow-up time was 4.0 years for all patients and 6.0 years for those alive at analysis. Rates of grade 3 and higher toxicity were 2.6% in arm 1 and 11.1% in arm 2. Median survival times (in years) for 34 Gy and 48 Gy were 4.1 versus 4.6, respectively. Five-year outcomes (95% confidence interval) for 34 Gy and 48 Gy were a primary tumor failure rate of 10.6% (3.3%-23.1%) versus 6.8% (1.7%-16.9%); overall survival of 29.6% (16.2%-44.4%) versus 41.1% (26.6%-55.1%); and progression-free survival of 19.1% (8.5%-33.0%) versus 33.3% (20.2%-47.0%). Distant failure as the sole failure or a component of first failure occurred in 6 patients (37.5%) in the 34 Gy arm and in 7 (41.2%) in the 48 Gy arm.ConclusionsNo excess in late-appearing toxicity was seen in either arm. Primary tumor control rates at 5 years were similar by arm. A median survival time of 4 years for each arm suggests similar efficacy, pending any larger studies appropriately powered to detect survival differences.

Published
2019

7. Accurate Real Time Localization Tracking in A Clinical Environment using Bluetooth Low Energy and Deep Learning

Author

Iqbal, Zohaib, Luo, Da, Henry, Peter, Kazemifar, Samaneh, Rozario, Timothy, Yan, Yulong, Westover, Kenneth, Lu, Weiguo, Nguyen, Dan, Long, Troy, Wang, Jing, Choy, Hak, and Jiang, Steve

Subjects
Physics - Medical Physics, Computer Science - Machine Learning
Abstract

Deep learning has started to revolutionize several different industries, and the applications of these methods in medicine are now becoming more commonplace. This study focuses on investigating the feasibility of tracking patients and clinical staff wearing Bluetooth Low Energy (BLE) tags in a radiation oncology clinic using artificial neural networks (ANNs) and convolutional neural networks (CNNs). The performance of these networks was compared to relative received signal strength indicator (RSSI) thresholding and triangulation. By utilizing temporal information, a combined CNN+ANN network was capable of correctly identifying the location of the BLE tag with an accuracy of 99.9%. It outperformed a CNN model (accuracy = 94%), a thresholding model employing majority voting (accuracy = 95%), and a triangulation classifier utilizing majority voting (accuracy = 95%). Future studies will seek to deploy this affordable real time location system in hospitals to improve clinical workflow, efficiency, and patient safety.

Published
2017
Full Text
View/download PDF

8. Shell feature: a new radiomics descriptor for predicting distant failure after radiotherapy in non-small cell lung cancer and cervix cancer

Author

Hao, Hongxia, Zhou, Zhiguo, Li, Shulong, Maquilan, Genevieve, Folkert, Michael R., Iyengar, Puneeth, Westover, Kenneth D., Albuquerque, Kevin, Liu, Fang, Choy, Hak, Timmerman, Robert, Yang, Lin, and Wang, Jing

Subjects
Physics - Medical Physics, Quantitative Biology - Tissues and Organs
Abstract

Purpose To develop and demonstrate a novel tumor shell feature for predicting distant failure in non-small cell lung cancer (NSCLC) and cervical cancer (CC) patients. Patients and Methods The shell predictive model was constructed using pretreatment positron emission tomography (PET) images from 48 NSCLC patients received stereotactic body radiation therapy (SBRT) and 52 CC patients underwent external beam radiation therapy and concurrent chemotherapy followed with high-dose-rate intracavitary brachytherapy. A shell feature, consisting of outer voxels around the tumor boundary, was extracted from a series of axial PET slices. The hypothesis behind this feature is that non-invasive and invasive tumors may have different morphologic patterns in the tumor periphery, in turn reflecting the differences in radiological presentations in the PET images. The utility of the shell was evaluated by the support vector machine (SVM) classifier in comparison with intensity, geometry, gray level co-occurrence matrix (GLCM) based texture, neighborhood gray tone difference matrix (NGTDM) based texture, and a combination of these four features. The results were assessed in terms of accuracy, sensitivity, specificity, and the area under the receiver operating curve (AUC). Results For NSCLC, the AUC achieved by the shell feature was 0.82 while the highest AUC achieved by the other features was 0.76. Similarly, for CC, the AUC achieved by the shell feature was 0.83 while the highest AUC achieved by the other features was 0.76. Also, the difference in performance between shell and the other features was significant (P < 0.005) in all cases. Conclusions We propose a boundary-based shell feature that correlates with tumor metastasis. The shell feature showed better predictive performance than all the other features for distant failure prediction in both NSCLC and CC., Comment: 12 pages,3 figures, 3 tables

Published
2017
Full Text
View/download PDF

9. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927)

Author

Videtic, Gregory MM, Hu, Chen, Singh, Anurag K, Chang, Joe Y, Parker, William, Olivier, Kenneth R, Schild, Steven E, Komaki, Ritsuko, Urbanic, James J, Timmerman, Robert D, and Choy, Hak

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Prevention, Patient Safety, Clinical Research, Lung, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Accreditation, Adult, Aged, Carcinoma, Non-Small-Cell Lung, Cause of Death, Confidence Intervals, Disease-Free Survival, Dose Fractionation, Radiation, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Patient Positioning, Radiosurgery, Radiotherapy, Radiotherapy Dosage, Survival Rate, Time Factors, Other Physical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis, Theoretical and computational chemistry, Medical and biological physics
Abstract

PurposeTo compare 2 stereotactic body radiation therapy (SBRT) schedules for medically inoperable early-stage lung cancer to determine which produces the lowest rate of grade ≥3 protocol-specified adverse events (psAEs) at 1 year.Methods and materialsPatients with biopsy-proven peripheral (≥2 cm from the central bronchial tree) T1 or T2, N0 (clinically node negative by positron emission tomography), M0 tumors were eligible. Patients were randomized to receive either 34 Gy in 1 fraction (arm 1) or 48 Gy in 4 consecutive daily fractions (arm 2). Rigorous central accreditation and quality assurance confirmed treatment per protocol guidelines. This study was designed to detect a psAEs rate >17% at a 10% significance level (1-sided) and 90% power. Secondary endpoints included rates of primary tumor control (PC), overall survival (OS), and disease-free survival (DFS) at 1 year. Designating the better of the 2 regimens was based on prespecified rules of psAEs and PC for each arm.ResultsNinety-four patients were accrued between September 2009 and March 2011. The median follow-up time was 30.2 months. Of 84 analyzable patients, 39 were in arm 1 and 45 in arm 2. Patient and tumor characteristics were balanced between arms. Four (10.3%) patients on arm 1 (95% confidence interval [CI] 2.9%-24.2%) and 6 (13.3%) patients on arm 2 (95% CI 5.1%-26.8%) experienced psAEs. The 2-year OS rate was 61.3% (95% CI 44.2%-74.6%) for arm 1 patients and 77.7% (95% CI 62.5%-87.3%) for arm 2. The 2-year DFS was 56.4% (95% CI 39.6%-70.2%) for arm 1 and 71.1% (95% CI 55.5%-82.1%) for arm 2. The 1-year PC rate was 97.0% (95% CI 84.2%-99.9%) for arm 1 and 92.7% (95% CI 80.1%-98.5%) for arm 2.Conclusions34 Gy in 1 fraction met the prespecified criteria and, of the 2 schedules, warrants further clinical research.

Published
2015

16. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases

Author

Wang, Chiachien Jake, Christie, Alana, Lin, Mu-Han, Jung, Matthew, Weix, Derek, Huelsmann, Lorel, Kuhn, Kristin, Meyer, Jeffrey, Desai, Neil, Kim, D. W. Nathan, Pedrosa, Ivan, Margulis, Vitaly, Cadeddu, Jeffrey, Sagalowsky, Arthur, Gahan, Jeffrey, Laine, Aaron, Xie, Xian-Jin, Choy, Hak, Brugarolas, James, Timmerman, Robert, and Hannan, Raquibul

Published
2017
Full Text
View/download PDF

19. List of Contributors

Author

Horn, Leora, primary, Gillaspie, Erin A., additional, Tsao, Ming-Sound, additional, Wakelee, Heather A., additional, Zweig, Jeffrey R., additional, Choy, Hak, additional, Jelinek, Michael J., additional, Liu, Stephen V., additional, Patel, Bhavisha A., additional, Sequist, Lecia V., additional, Hui, Rina, additional, Mendel, J. Travis, additional, Gadgeel, Shirish, additional, Patel, Jyoti D., additional, Millward, Michael, additional, Dickinson, Emily, additional, Reckamp, Karen L., additional, Zhao, Dan, additional, Pal, Prodipto, additional, Cabanero, Michael, additional, and Marcoux, Nicolas, additional

Published
2019
Full Text
View/download PDF

22. Figure S2 from Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma

Author

Hannan, Raquibul, primary, Mohamad, Osama, primary, Diaz de Leon, Alberto, primary, Manna, Subrata, primary, Pop, Laurentiu M., primary, Zhang, Ze, primary, Mannala, Samantha, primary, Christie, Alana, primary, Christley, Scott, primary, Monson, Nancy, primary, Ishihara, Dan, primary, Hsu, Eric J., primary, Ahn, Chul, primary, Kapur, Payal, primary, Chen, Mingyi, primary, Arriaga, Yull, primary, Courtney, Kevin, primary, Cantarel, Brandi, primary, Wakeland, Edward K., primary, Fu, Yang-Xin, primary, Pedrosa, Ivan, primary, Cowell, Lindsay, primary, Wang, Tao, primary, Margulis, Vitaly, primary, Choy, Hak, primary, Timmerman, Robert D., primary, and Brugarolas, James, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Data from Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma

Author

Hannan, Raquibul, primary, Mohamad, Osama, primary, Diaz de Leon, Alberto, primary, Manna, Subrata, primary, Pop, Laurentiu M., primary, Zhang, Ze, primary, Mannala, Samantha, primary, Christie, Alana, primary, Christley, Scott, primary, Monson, Nancy, primary, Ishihara, Dan, primary, Hsu, Eric J., primary, Ahn, Chul, primary, Kapur, Payal, primary, Chen, Mingyi, primary, Arriaga, Yull, primary, Courtney, Kevin, primary, Cantarel, Brandi, primary, Wakeland, Edward K., primary, Fu, Yang-Xin, primary, Pedrosa, Ivan, primary, Cowell, Lindsay, primary, Wang, Tao, primary, Margulis, Vitaly, primary, Choy, Hak, primary, Timmerman, Robert D., primary, and Brugarolas, James, primary

Published
2023
Full Text
View/download PDF

24. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis

Author

De Ruysscher, D., Le Pechoux, C., Lueza, B., Paris, E., Pignon, J.P., Pijls-Johannesma, M., Veillard, A.S., Arriagada, Rodrigo, Baas, Paul, Blackstock, William, Chevret, Sylvie, Choy, Hak, Crawford, Jeffrey, Dafni, Urania, Dahlberg, Suzanne, De Ruysscher, Dirk, Hackshaw, Allan, Hasan, Baktiar, Johnson, David H., Le Pechoux, Cécile, Lebeau, Bernard, Lovato, James, Lueza, Béranger, Murray, Nevin, O’Brien, Mary, Paris, Emmanuelle, Pignon, Jean-Pierre, Pijls-Johannesma, Madelon, Price, Allan, Spiro, Stephen, Seymour, Lesley, Shibata, Taro, Skarlos, Dimosthenis, Takada, Minoru, Veillard, Anne-Sophie, Wang, Xiaofei, Le Péchoux, C., Johnson, D.H., O'Brien, M., Murray, N., Spiro, S., Wang, X., Takada, M., Lebeau, B., Blackstock, W., Skarlos, D., Baas, P., Choy, H., Price, A., Seymour, L., Arriagada, R., and Pignon, J.-P.

Published
2016
Full Text
View/download PDF

26. Contributors

Author

Adjei, Alex A., primary, Ahn, Mjung-Ju, additional, Amos, Chris I., additional, Antonicelli, Alberto, additional, Asamura, Hisao, additional, Atwood, Todd, additional, Baas, Paul, additional, Bailey-Wilson, Joan E., additional, Ball, David, additional, Barlesi, Fabrice, additional, Bazan, Jose G., additional, Belderbos, José, additional, Bezjak, Andrea, additional, Billingham, Lucinda J., additional, Boffetta, Paolo, additional, Bonifazi, Martina, additional, Brahmer, Julie R., additional, Brambilla, Elisabeth, additional, Brims, Fraser, additional, Brunelli, Alessandro, additional, Bryant, Ayesha, additional, Campbell, Nicholas, additional, Carter, Brett W., additional, Cerfolio, Robert, additional, Cho, Byoung Chul, additional, Cho, William C.S., additional, Choy, Hak, additional, Chu, Chia-Yu, additional, Colburn, Glenda, additional, Colt, Henri, additional, Rosell Costa, Rafael, additional, Darling, Gail E., additional, Davis, Mellar, additional, de Groot, Patricia M., additional, de Koning, Harry J., additional, De Leyn, Paul, additional, De Ruysscher, Dirk, additional, Demiral, Ayşe Nur, additional, Derks, Jules, additional, Detterbeck, Frank C., additional, Devarakonda, Siddhartha, additional, Dingemans, Anne-Marie C., additional, Donington, Jessica S., additional, Dresler, Carolyn M., additional, Dubinett, Steven M., additional, Dy, Grace K., additional, Erasmus, Jeremy J., additional, Fairchild, Alysa, additional, Fennell, Dean A., additional, Fernando, Hiran C., additional, Filosso, Pier Luigi, additional, Flores, Raja, additional, Fong, Kwun, additional, Fox, Jesme, additional, Gandara, David R., additional, Gandhi, Leena, additional, Gaspar, Laurie, additional, Gasparini, Stefano, additional, Gazdar, Adi F., additional, Giaccone, Giuseppe, additional, Girard, Nicolas, additional, Goldstraw, Peter, additional, Gore, Elizabeth M., additional, Goss, Glenwood, additional, Govindan, Ramaswamy, additional, Greenberg, Alissa K., additional, Grunenwald, Dominique, additional, Guckenberger, Matthias, additional, Gulati, Swati, additional, Hassan, Raffit, additional, Hazzard, Christopher, additional, Hegi, Fiona, additional, Hensing, Thomas, additional, Herbst, Roy, additional, Hirsch, Fred R., additional, Horeweg, Nanda, additional, Jablons, David M., additional, Jett, James R., additional, Kaufman, Andrew, additional, Keall, Paul, additional, Kelly, Karen, additional, Kong, Feng-Ming (Spring), additional, Kubota, Kaoru, additional, Laird-Offringa, Ite A., additional, Lara, Primo N., additional, Laskin, Janessa, additional, Le, Quynh-Thu, additional, Le Péchoux, Cécile, additional, Liclican, Elvira L., additional, Lievens, Yolande, additional, Lin, Chia-Chi (Josh), additional, Loo, Billy W., additional, Manus, Michael Mac, additional, Macapinlac, Homer A., additional, Macbeth, Fergus, additional, Mackillop, William J., additional, Maher, Christopher, additional, Mambetsariev, Isa, additional, Mandrekar, Sumithra J., additional, Mansfield, Aaron S., additional, Marks, Lawrence B., additional, Mascaux, Céline, additional, Massion, Pierre P., additional, Mazieres, Julien, additional, McWilliams, Annette, additional, Mitsudomi, Tetsuya, additional, Mok, Tony, additional, Morgensztern, Daniel, additional, Mornex, Francoise, additional, Mulshine, James L., additional, Munden, Reginald F., additional, Nackaerts, Kristiaan, additional, Nakamichi, Shinji, additional, Noguchi, Masayuki, additional, Noonan, Krista, additional, Novello, Silvia, additional, Nowak, Anna K., additional, O’Byrne, Kenneth J., additional, Ohri, Nisha, additional, Okada, Morihito, additional, Ostroff, Jamie S., additional, Parikh, Mamta, additional, Park, Elyse R., additional, Park, Keunchil, additional, Pass, Harvey I., additional, Pastis, Nicholas, additional, Paz-Ares, Luis, additional, Pennell, Nathan, additional, Perol, Maurice, additional, Pillai, Rathi N., additional, Postmus, Pieter E., additional, Ramalingham, Suresh S., additional, Ramella, Sara, additional, Rami-Porta, Ramón, additional, Reck, Martin, additional, Redman, Mary W., additional, Reinmuth, Niels, additional, Ricardi, Umberto, additional, Rice, David, additional, Ridge, Carole A., additional, Rom, William N., additional, Rosenzweig, Kenneth E., additional, Ruffini, Enrico, additional, Rusch, Valerie W., additional, Salgia, Ravi, additional, Sanchez-Cespedes, Montse, additional, Saqi, Anjali, additional, Scagliotti, Giorgio V., additional, Schimmel, Selma, additional, Schwartz, Ann G., additional, Senan, Suresh, additional, Shepherd, Francis A., additional, Siegfried, Jill M., additional, Silvestri, Gerard A., additional, Simon, George R., additional, Smit, Egbert F., additional, Solomon, Stephen B., additional, Stabile, Laura P., additional, Steliga, Matthew A., additional, Stinchcombe, Thomas E., additional, Stollenwerk, Nicholas S., additional, Sun, Jong-Mu, additional, Thomas, Anish, additional, Tsao, Ming-Sound, additional, Tsay, Jun-Chieh J., additional, Van Houtte, Paul, additional, Van Schil, Paul E., additional, van Zandwijk, Nico, additional, Vansteenkiste, J.F., additional, Varella-Garcia, Marileila, additional, Veronesi, Giulia, additional, Vinod, Shalini K., additional, Vokes, Everett E., additional, Wakelee, Heather, additional, Walser, Tonya C., additional, Watanabe, Shun-ichi, additional, Weder, Walter, additional, Wei, Benjamin, additional, Wistuba, Ignacio I., additional, Yang, James Chih-Hsin, additional, Yankelevitz, David F., additional, Yasufuku, Kazuhiro, additional, Yoneda, Ken Y., additional, Zalcman, Gérard, additional, Zhou, Caicun, additional, Zhou, Yang, additional, and Zips, Daniel, additional

Published
2018
Full Text
View/download PDF

29. Definitive radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline

Author

Rodrigues, George, Choy, Hak, Bradley, Jeffrey, Rosenzweig, Kenneth E., Bogart, Jeffrey, Curran, Walter J., Jr., Gore, Elizabeth, Langer, Corey, Louie, Alexander V., Lutz, Stephen, Machtay, Mitchell, Puri, Varun, Werner-Wasik, Maria, and Videtic, Gregory M.M.

Published
2015
Full Text
View/download PDF

30. Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline

Author

Rodrigues, George, Choy, Hak, Bradley, Jeffrey, Rosenzweig, Kenneth E., Bogart, Jeffrey, Curran, Walter J., Jr., Gore, Elizabeth, Langer, Corey, Louie, Alexander V., Lutz, Stephen, Machtay, Mitchell, Puri, Varun, Werner-Wasik, Maria, and Videtic, Gregory M.M.

Published
2015
Full Text
View/download PDF

31. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

Author

Bradley, Jeffrey D, Paulus, Rebecca, Komaki, Ritsuko, Masters, Gregory, Blumenschein, George, Schild, Steven, Bogart, Jeffrey, Hu, Chen, Forster, Kenneth, Magliocco, Anthony, Kavadi, Vivek, Garces, Yolanda I, Narayan, Samir, Iyengar, Puneeth, Robinson, Cliff, Wynn, Raymond B, Koprowski, Christopher, Meng, Joanne, Beitler, Jonathan, Gaur, Rakesh, Curran, Walter, Jr, and Choy, Hak

Published
2015
Full Text
View/download PDF

37. T Stage and Pretreatment Standardized Uptake Values Predict Tumor Recurrence With 5-Fraction SABR in Early-Stage Non-Small Cell Lung Cancer

Author

Hsu, Eric J., primary, Mendel, Jameson T., additional, Ward, Kristin A., additional, El-Ashmawy, Mariam, additional, Lee, Minjae, additional, Choy, Hak, additional, Westover, Kenneth D., additional, Vo, Dat T., additional, Timmerman, Robert D., additional, Sher, David J., additional, and Iyengar, Puneeth, additional

Published
2022
Full Text
View/download PDF

41. Lung Cancer

Author

Choy, Hak, Pass, Harvey I., Rosell, Rafael, Traynor, Anne, Chang, Alfred E., editor, Hayes, Daniel F., editor, Pass, Harvey I., editor, Stone, Richard M., editor, Ganz, Patricia A., editor, Kinsella, Timothy J., editor, Schiller, Joan H., editor, and Strecher, Victor J., editor

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results